Cytek Biosciences (CTKB) Other Non-Current Liabilities (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Other Non-Current Liabilities data on file, last reported at $2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 0.76% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 million (up 0.76% YoY), and the FY2025 full-year result was $2.3 million, down 2.41% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $2.4 million, up from $2.3 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $2.5 million in Q3 2025 and bottomed at $1.1 million in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $2.1 million (2024), against an average of $2.0 million.
• The widest annual swing landed in 2022, when Other Non-Current Liabilities soared 94.98%; it then slipped 12.13% in 2024.
• A 5-year view of Other Non-Current Liabilities shows it stood at $1.6 million in 2022, then surged by 53.18% to $2.4 million in 2023, then retreated by 2.76% to $2.4 million in 2024, then decreased by 2.41% to $2.3 million in 2025, then gained by 3.94% to $2.4 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.4 million (Q1 2026), $2.3 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.

Peer Comparison